Seres Therapeutics Q3 net income $8.2 mln, reverses loss

Seres Therapeutics

05/11/2025 12:25

Overview

Seres Therapeutics reports Q3 net income of $8.2 mln, reversing a loss from last year

Company reduces operating expenses through cost-reduction measures, including workforce reductions

Seres finalizing SER-155 Phase 2 study protocol, interim results expected within 12 months

Seres receives $3.6 mln CARB-X grant for SER-155 development

Outlook

Seres expects interim results from SER-155 Phase 2 study within 12 months of initiation

Company anticipates initial results from immune checkpoint enterocolitis study in early 2026

Seres expects to fund operations through Q2 2026

Result Drivers

COST REDUCTION - Seres implemented cost-reduction measures, including workforce reductions, to fund operations through Q2 2026

CARB-X GRANT - Seres received a $3.6 mln grant from CARB-X to support the development of an oral liquid formulation of SER-155

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$351,000
Q3 EPS
$0.94
Q3 Net Income
$8.20 mln
Q3 Operating Expenses
$22.82 mln
Q3 Operating Income
-$22.47 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Seres Therapeutics Inc is $20.00, about 31.3% above its November 4 closing price of $13.75

Press Release: ID:nGNX2g2PnC

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)